ABL Bio Submits IND Application for Phase 1 Clinical Trial of ABL209 in the US
NeokBio Leads Development
Phase 1 Clinical Trials Targeted to Begin Mid-Year
ABL Bio, a company specializing in bispecific antibodies, announced on February 2 that it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) on January 30 (local time) for a Phase 1 clinical trial of its bispecific antibody-drug conjugate (ADC) candidate, ABL209 (NEOK002).
ABL209 is an ADC candidate that combines a bispecific antibody targeting both EGFR and MUC1?proteins expressed on the surface of cancer cells?with a topoisomerase I inhibitor. According to the company, non-clinical studies have demonstrated superior anti-cancer efficacy compared to ADCs based on single antibodies.
The global clinical development of ABL209 is being led by NeokBio, a bispecific antibody ADC development company established by ABL Bio in the United States. NeokBio holds global development and commercialization rights for both ABL209 and ABL206 (NEOK001).
ABL206 received IND approval from the FDA for a Phase 1 clinical trial last month. NeokBio plans to initiate Phase 1 clinical trials for both candidates around mid-2026 and release early clinical data during 2027.
ABL Bio is developing multiple clinical and preclinical pipelines based on its bispecific antibody platform, Grabody. Currently, nine pipelines?ABL301, ABL001, ABL111, ABL503, ABL105, ABL104, ABL103, ABL202, and ABL206?are in clinical stages in the United States, China, Australia, and Korea.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The subsequent clinical trials for ABL301 are being conducted by Sanofi. ABL001 has received Fast Track designation from the FDA. ABL111 has shown initial efficacy data in combination immuno-oncology clinical trials.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.